Interestingly, these cases have shown response to a dual EGFR/MET blockade mediated by erlotinib/crizotinib combination [34, 35], thereby illustrating feasibility and therapeutic potential of combinatorial strategies in EGFR-mutant NSCLC with activation of bypass signaling pathways, such as MET-amplification. Here, EGFR is linked to non-small cell lung carcinoma.